LN-145

autologous tumor-infiltrating lymphocytes · Iovance Biotherapeutics, Inc.

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for LN-145, covering 2023-10-12 to 2026-07-31. Get the full timeline:

Most recent: Clinical Trial Results: Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma [Phase 2]

See pricing